Skip to content
Portage Biotech
Portage BiotechPortage Biotech
  • about us
    • overview
    • leadership
  • our pipeline
    • iNKT platform
    • adenosine platform
    • other programs in development
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • join our team
  • contact
  • about us
    • overview
    • leadership
  • our pipeline
    • iNKT platform
    • adenosine platform
    • other programs in development
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • join our team
  • contact

Daily Archives: August 5, 2021

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

Press ReleaseBy Portage Biotech, IncAugust 5, 2021
...

The Bio Report: Taking a Portfolio Approach to Immuno-Oncology

Media CoverageBy Portage Biotech, IncAugust 5, 2021
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top